

1 **Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or**
2 **vector-based COVID-19 vaccinations**

3 Henning Jacobsen^{#,1}, Monika Strengert^{#,2,3}, Henrike Maaß^{*,1}, Mario Alberto Ynga Durand^{*,1}, Barbora
4 Kessel², Manuela Harries², Ulfert Rand¹, Leila Abassi¹, Yeonsu Kim¹, Tatjana Lüddecke¹, Pilar Hernandez²,
5 Julia Ortmann², Jana-Kristin Heise², Stefanie Castell², Daniela Gornyk², Stephan Glöckner², Vanessa
6 Melhorn², Yvonne Kemmling², Berit Lange^{2,5}, Alex Dulovic⁴, Julia Häring⁴, Daniel Junker⁴, Nicole
7 Schneiderhan-Marra⁴, Markus Hoffmann^{6,7}, Stefan Pöhlmann^{6,7}, Gérard Krause^{2,3,5,§}, Luka Cicin-Sain^{1,5,8,§}

8 1 Helmholtz Centre for Infection Research, Department of Viral Immunology, Braunschweig, Germany

9 2 Helmholtz Centre for Infection Research, Department of Epidemiology Braunschweig, Germany

10 3 TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture of the Hannover
11 Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany

12 4 NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany

13 5 German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig, Germany

14 6 Deutsches Primatenzentrum, Leibniz-Institut für Primatenforschung, Göttingen, Germany

15 7 Faculty of Biology and Psychology, Georg-August-University Göttingen, Germany

16 8 Centre for Individualized Infection Medicine (CIIM), a joint venture of Helmholtz Centre for Infection
17 Research and Medical School Hannover, Germany

18
19 # (first authors), * (second authors), § (corresponding authors): these authors contributed equally.

20
21 Corresponding authors contact details:

22 Luka Cicin-Sain, Phone number: +49 (0)53161814616, Email address: luka.cicin-sain@helmholtz-hzi.de,

23 Postal address: Inhoffenstraße 7, 38124 Braunschweig, Germany.

24

25

26 **Abstract**

27 SARS-CoV-2 variants accumulating immune escape mutations provide a significant risk to vaccine-
28 induced protection. The novel variant of concern (VoC) Omicron (B.1.1.529) has the largest number of
29 amino acid alterations in its Spike protein to date. Thus, it may efficiently escape recognition by neutralizing
30 antibodies, allowing breakthrough infections in convalescent and vaccinated individuals. We analyzed
31 neutralization activity of sera from individuals after vaccination with all mRNA-, vector- or heterologous
32 immunization schemes currently available in Europe by *in vitro* neutralization assay at peak response
33 towards SARS-CoV-2 B.1, Omicron, Beta and Delta pseudotypes and also provide longitudinal follow-up
34 data from BNT162b2 vaccinees. All vaccines apart from Ad26.CoV2.S showed high levels of responder
35 rates (93-100%) towards SARS-CoV-2 wild-type, but some reductions in neutralizing Beta and Delta VoC
36 pseudotypes. The novel Omicron variant had the biggest impact, both in terms of response rates and
37 neutralization titers. Only mRNA-1273 showed a 100% response rate to Omicron and induced the highest
38 level of neutralizing antibody titers, followed by heterologous prime-boost approaches. Homologous
39 BNT162b2 vaccination or vector-based AZD1222 or Ad26.CoV2.S performed less well with peak
40 responder rates of 33%, 50% and 9%, respectively. However, Omicron responder rates in BNT162b2
41 recipients were maintained in our six month longitudinal follow-up indicating that individuals with cross-
42 protection against Omicron maintain it over time. Overall, our data strongly argues for urgent booster doses
43 in individuals who were previously vaccinated with BNT162b2, or a vector-based immunization scheme.

44 **Keywords**

45 SARS-CoV-2, Omicron B.1.1.529, variants of concern, protective immunity, neutralization, COVID-19
46 vaccination

47

48

49 1. Introduction

50 Since its emergence in late 2019, SARS-CoV-2 has caused a pandemic with more than 270 million
51 confirmed infections and more than 5 million deaths (1). While a series of vaccines have been developed
52 with unprecedented speed and were successfully deployed to limit the burden of COVID-19, it became
53 quickly apparent that novel SARS-CoV-2 variants had evolved, mainly in areas of high virus prevalence.
54 Those emerging variants have accumulated mutations in the surface-exposed Spike protein, which increase
55 virus transmissibility or promote evasion from the host immune response (2-4). Immune escape was most
56 pronounced in SARS-CoV-2 variants Beta (B.1.351) and the currently globally dominating Delta
57 (B.1.617.2), at least until recently. However, the November 2021 emergence of the variant B.1.1.529
58 (Omicron) in South Africa has raised strong concerns as its unusually high number of amino acid alterations
59 in the Spike protein will likely contribute to an increased reinfection risk or breakthrough infections
60 following vaccination (5). By now, a series of studies using samples from convalescent and vaccinated
61 individuals have addressed the impact of Omicron on vaccination or infection-induced antibody
62 neutralization, using either live-, pseudovirus neutralization or *in vitro* binding assays (6-14). These studies
63 have shown clear losses of neutralization capacity against the Omicron variant but did not comprehensively
64 address antibody responses in various vaccination regimens or over time. In contrast, we provide here a
65 comprehensive assessment of vaccination schemes approved in the European Union and the UK, using an
66 Omicron, Beta, Delta or wild-type (B.1) pseudo-neutralization assay at peak response after approximately
67 four weeks and in a longitudinal six month follow-up for BNT162b2.

68 2. Methods

69 2.1 Sample collection and ethics statement

70 Serum samples analysed in this study originate from vaccinated participants of the multi-local and serial
71 cross-sectional prevalence study on antibodies against SARS-CoV-2 in Germany (MuSPAD) study, a
72 population-based SARS-CoV-2 seroprevalence study in eight regions of Germany from July 2020 to
73 August 2021. The study was approved by the Ethics Committee of the Hannover Medical School
74 (9086_BO_S_2020) and was in line with the Declaration of Helsinki. Briefly, MuSPAD is a successive
75 cross-sectional study where certain locations were sampled longitudinally within a 3-4 month interval (15).
76 Recruitment of eligible participants (>18 years) was based on age- and sex-stratified random sampling with
77 information provided by the respective local residents' registration offices. Basic sociodemographic data
78 and information on pre-existing medical conditions including a previous SARS-CoV-2 infection or
79 vaccination are self-reported and were documented with the Research system PIA (Prospective Monitoring
80 and Management-App) at the study center. Peripheral blood was obtained by venipuncture using a serum
81 gel S-Monovette (Sarstedt) and further processed according to the manufacturer's instructions. Serum was
82 then aliquoted at the German Red Cross Institute of Transfusion Medicine and Immunohematology and
83 transported on dry ice to the Hannover Unified Biobank for long-term storage.

84 For this study, we selected samples from 82 vaccinees from the available MuSPAD sample pool to contain
85 mRNA, vector and heterologous immunization schemes. Selection was primarily based on a consistent 21-
86 35 day ΔT range from a complete vaccination until sampling with comparable age and gender distribution
87 between vaccination schemes, if available paired longitudinal follow-up samples were selected of samples
88 taken at peak response. None of the donors reported a positive SARS-CoV-2 antigen or PCR test result
89 when questioned at the study center at the time of the blood draw. Additionally, all collected serum samples
90 were non-reactive for nucleocapsid-specific IgG as determined with a previously published multiplex
91 immunoassay MULTICOV-AB that contains SARS-CoV-2 Spike and nucleocapsid antigens
92 (Supplementary Table S3, (16)), therefore excluding confounders due to infections superposed on
93 vaccination in our cohort. Vaccination details with basic sociodemographic information and pre-existing
94 conditions such as hypertension, cardiovascular disease, diabetes, lung disease, immunosuppression or
95 cancer of participants are provided in Table 1 and Supplementary Table S1. As controls, the first WHO
96 International Standard for human anti-SARS-CoV-2 immunoglobulin (code: 20/136) from the National

97 Institute for Biological Standards and Control (NIBSC) or pre-pandemic sera samples from an anonymized
98 Hepatitis A and Influenza virus vaccination response study at the Helmholtz Centre for Infection Research
99 in 2014 (Hannover Medical School Ethics Committee approval number 2198-2021) were used.

100 *2.2 Cell culture*

101 Vero E6 (ATCC CRL-1586), and 293T (DSMZ ACC-635) were maintained in DMEM medium
102 supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml
103 streptomycin at 37 °C in a 5% CO₂ atmosphere. All cell lines used within this study were below a passage
104 of 50 and were regularly checked for mycoplasma contamination. Transfection of 293T cells was performed
105 using calcium-phosphate.

106 *2.3 Plasmids*

107 Plasmids encoding SARS-CoV-2 Spike B.1 (human codon optimized, 18 amino acid truncation at C-
108 terminus) and SARS-CoV-2 spike of Beta (B.1.351) and Delta (B.1.617.2) have been previously reported
109 (17-19). The expression vector for SARS-CoV-2 Spike of Omicron (based on isolate hCoV-
110 19/Botswana/R40B58_BHP_3321001245/2021; GISAID Accession ID: EPI_ISL_6640919) was
111 generated by Gibson assembly (13). All plasmids were sequence-confirmed by Sanger sequencing prior to
112 use. Supplementary Table S2 provides an overview of Spike protein amino acid mutations used for SARS-
113 CoV-2 pseudotype construction compared to the parental strain B.1.

114 *2.4 Pseudotyping*

115 Generation of rhabdoviral pseudotypes harboring SARS-CoV-2 Spike proteins was performed as described
116 (20). In brief, 293T cells were transfected with pCG1 plasmids expressing different SARS-CoV-2 Spike
117 proteins, using calcium-phosphate. 24 h post transfection, cells were infected with a replication-deficient
118 reporter VSV-G (VSV*ΔG-Fluc) at an MOI of 3 for 1 h at 37 °C (21). Cells were washed once with PBS
119 and medium containing anti-VSV-G antibody (culture supernatant from L1-hybridoma cells) was added to
120 neutralize residual input virus. The cell culture supernatant was harvested after 16 hours, and cellular debris
121 was removed by centrifugation at 2000 g for 5 min at 4 °C. Aliquots were stored at -80°C until use.

122 *2.5 Neutralization assay*

123 For pseudovirus neutralization, serum samples and controls were heat-inactivated at 56 °C for 30 min.
124 Thawed samples and controls were stored at 4°C for no longer than 48 hours, prior to use. In a 96-well
125 microtiter plate, serum samples were 2-fold serially diluted in cell culture medium (DMEM, 5 % FBS, 1%
126 P/S, 1% L-Glu) with a dilution range of 1:10 to 1:5120. Pre-diluted samples were incubated with an equal
127 volume of Spike protein-bearing viral particles (approximately 200 - 500 ffu/well) at 37 °C for 1 h. After
128 incubation, the sample-virus mixture was transferred to VeroE6 cells at 100% confluence which were
129 seeded the day before. Cells were incubated at 37 °C for 24±2 h, while infected cells were visualized using
130 an IncuCyte S3 (Sartorius) performing whole-well scans (4x) in phase contrast and green fluorescence
131 settings. Automated segmentation and counting of fluorescent foci defined as GFP⁺-single cells was
132 performed using the IncuCyte GUI software (versions 2019B Rev1 and 2021B). Raw data were plotted in
133 GraphPad prism version 9.0.2 and FRNT₅₀ was calculated with a variable slope, four- parameter regression
134 analysis. Non-responders were defined as subjects with undetectable neutralization titers at an initial serum
135 dilution of 1:10. FRNT₅₀ values of those individuals were arbitrarily set to 1. All experiments were
136 performed with internal standard controls (pool of all tested sera), negative controls and virus-only controls
137 to assess the nominal virus input for every single measurement.

138 *2.6 Data analysis and statistics*

139 Initial results collation and matching to metadata was done in Excel 2016 and R 4.1.0. Graphs and statistical
140 calculations were performed using GraphPad Prism version 9.0.2 for Windows (GraphPad Software). For
141 analysis of neutralization assay results, a Shapiro-Wilk test was used to determine normality. Focus

142 Reduction Neutralization titer with a 50% neutralization cut-off (FRNT₅₀) was calculated using a four-
143 parameter regression analysis function. FRNT₅₀ values from non-responders were set to 1 for graphical
144 presentation only. A non-parametric Friedman's test followed by Dunn's multiple comparison analysis was
145 used to compare neutralization results to different viruses in a pair-wise manner for matched samples. Two-
146 tailed Wilcoxon matched-pairs signed rank test was used to compare neutralization of longitudinal results.
147 A p-value of less than 0.05 was considered statistically significant.

148 *2.7 Role of the funders*

149 This work was financially supported by the Initiative and Networking Fund of the Helmholtz Association
150 of German Research Centres through projects “Virological and immunological determinants of COVID-19
151 pathogenesis – lessons to get prepared for future pandemics (KA1-Co-02 “COVIPA”) to LCS and grant
152 number SO-96 to GK, by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
153 under Germany’s Excellence Strategy – EXC 2155 “RESIST” – Project ID 39087428 to LCS, and
154 intramural funds of the Helmholtz Centre for Infection Research. SP was supported by BMBF (01KI2006D,
155 01KI20328A, 01KX2021), the Ministry for Science and Culture of Lower Saxony (14-76103-184, MWK
156 HZI COVID-19) and the German Research Foundation (DFG; PO 716/11-1, PO 716/14-1). The funders
157 had no role in study design, data collection, data analysis, interpretation, writing or submission of the
158 manuscript. All authors had complete access to the data and hold responsibility for the decision to submit
159 for publication.

160 **3. Results**

161 Neutralization responses towards B.1, B.1.1.529, B.1.351, and B.1.617.2 Spike-expressing rhabdoviral
162 pseudotypes were analyzed in serum samples from 82 individuals vaccinated with either a single dose of
163 Ad26.COVS.2.S, homologous two-dose BNT162b2, mRNA-1273 or AZD1222 vaccination, or heterologous
164 AZD1222-BNT162b2 or AZD1222-mRNA-1273 vaccination at peak response, approximately four weeks
165 after the last dose. While the WHO international standard serum showed detectable neutralization against
166 all variants including Omicron, showing excellent sensitivity of our assay, compared to previous studies
167 (22), pre-pandemic control sera from 2014 (n=4) showed no measurable neutralization levels
168 (Supplementary Table S3). Neutralization potency towards Beta VoC pseudotypes were clearly reduced for
169 all vaccination schemes, however Omicron had the strongest effect across all samples tested (Fig. 1).
170 Vaccination with vector-based Ad26.CoV2.S performed least well (Fig. 1a), with only 73% responders
171 against the B.1 variant, 18% for the Beta and 9% for Omicron VoC. Homologous vaccination with either
172 AZD1222 or BNT162b2 performed better against Omicron, with 50% or 33% responders, respectively
173 (Fig. 1b, 1c). Heterologous immunization with these two vaccines (AZD1222-BNT162b2) showed a
174 response rate of 80% (Fig. 1d). Heterologous vaccination with AZD1222-mRNA-1273 had a similar
175 response rate of 82% (Fig. 1e), but homologous immunization with mRNA-1273 had the highest Omicron
176 response rate of 100% (Fig. 1f). Non-parametrical statistical comparisons showed a highly significant
177 reduction in serum titers when Omicron neutralization was compared to B.1 for all vaccination schemes
178 (Fig 1a-e). There was no tendency of age, sex, or pre-existing medical conditions to modify the responder
179 status against Omicron in our cohort (Supplementary Table S3). To assess the impact of immune escape
180 with more detail, we focused on the responders and compared geometric means of their FRNT₅₀ titers
181 (GMT). Importantly, fold-changes for groups that included non-responders are not provided in Fig. 1,
182 because this would lead to highly artificial results and possibly over-interpretation. We therefore present
183 the percentage of responders as primary outcome and provide GMT fold changes where calculation is
184 reasonable (100% responders in both arms). Furthermore, for each vaccination regimen, we defined the
185 responder subgroups (excluding non-responders defined as subjects with undetectable neutralization titers
186 at an initial 1:10 serum dilution in either group) and compared the fold-reduction for titers that could be
187 quantified (see Table 2). In these subsets, we observed an approximate 15-fold reduction in GMT for most
188 vaccinations, except BNT162b2, where the reduction was 28-fold at peak response. This was consistent

189 with the high frequency of non-responders in this subset, additionally arguing for weaker protection against
190 the Omicron variant in this cohort.

191 Since BNT162b2 is very commonly used, we tested the neutralization potency in BNT162b2 recipients at
192 approximately six months post immunization as well. Similar to the peak responses, we observed a
193 significantly weaker neutralization of the Omicron compared to the B.1 pseudotype and only 47%
194 responders against the newly emerging VoC (Fig. 2a). Beta neutralization was slightly reduced, whereas
195 Delta neutralization was at the same levels as B.1 at the late time point (Fig. 2a). To understand the
196 longitudinal dynamic of humoral immunity, we used paired sera from BNT162b2 vaccine recipients at four
197 weeks (already shown in Fig. 1c) and at six months post second dose which allowed us to compare intra-
198 individual titer changes over time (Fig. 2b-d). While the neutralization of B.1 (Fig. 2b) and of the Delta
199 VoC (Fig. 2d) decreased significantly over time, the time dependent reduction was less pronounced for the
200 Beta (Fig. 2c) or the Omicron VoC (Fig. 2e). Moreover, all Omicron responders identified early after
201 vaccination had still detectable neutralizing capacity at the late time points and two additional responders
202 were identified in the late phase only (Fig. 2e). Therefore, the differences in neutralization titers between
203 B.1 and Omicron responders were less pronounced at the late time points than at peak response (Table 2).

204 In sum, homologous mRNA-1273 vaccination resulted in the highest responder rate, Ad26.CoV2.S in the
205 lowest within the vaccination peak response phase, and a longitudinal follow-up showed that Omicron
206 responses, while reduced, can be rather durable if present in the first place.

207 Discussion

208 We provide a comprehensive overview of neutralization responses from all currently available COVID-19
209 vaccination schemes in the European Union and the UK not only towards the Omicron VoC, but also
210 towards Beta and Delta VoC compared to the parental strain B.1. We expand on previous findings (11, 12)
211 that neutralization towards Omicron is particular poor after vaccination with vector-based formulations
212 even within the peak phase shortly after vaccination. Also consistent with other reports (13, 14), we
213 observed a still surprisingly low cross-neutralization in BNT162b2 recipients. While some time differences
214 exist between doses for homologous and heterologous vaccines, sampling periods after the complete
215 scheme were within peak response making an earlier waning of BNT162b2-induced antibodies highly
216 unlikely. While age impacts antibody titers and neutralization potency (23-25), our group of BNT162b2
217 recipients is slightly younger compared to the other vaccinees making age an unlikely contributor to our
218 observation. Additionally, no tendency became apparent for gender and comorbidities either. Considering
219 our relatively small sample size, it is however possible that this low overall response in the BNT162b2
220 group was a spurious observation. Nevertheless, samples showing any cross-neutralizing responses early
221 on remained responsive to Omicron six months later. Notably, all mRNA-1273 recipients and 80% of those
222 receiving any heterologous vaccination showed a detectable neutralization against Omicron in our analysis.
223 It is not clear, why these vaccination protocols were more efficient against the Omicron pseudotype than
224 BNT162b2, but it is indicative that the baseline neutralization against the B.1 pseudotype was stronger in
225 all of them in our sample cohorts.

226 The detectable responsiveness to the Omicron pseudotype in all mRNA-1273 recipients differed from
227 previous reports where usually several samples showed no measurable neutralization against Omicron (12,
228 14, 26). This might be due to sampling differences, a result of increased sensitivity in our assay, or both.
229 We chose responder rates as primary outcome because this is a less biased expression than fold changes if
230 titers from non-responsive individuals are calculated. For the same reason, we used a non-parametric assay
231 to evaluate differences, allowing us to include samples that were below detection threshold, but obviously
232 very low in titer. Fold changes were calculated separately on a subset of samples that showed detectable
233 titers in all circumstances. We observed an approximately 15-fold reduction in most vaccination regimens
234 except BNT162b2, adding evidence that Omicron cross-neutralization was impaired in this cohort. Our
235 studies has several limitations. First, sample numbers in our cohort are low. They are however comparable
236 to the majority of other studies to date and are well-matched on age and sex. Second, while our mean 55

237 day sampling time period after Ad26.CoV2.S administration is slightly longer than the four week sampling
238 interval of the other vaccination schemes, our results are in line with others who reported poor Omicron
239 neutralization following vaccination with Ad26.CoV2.S both at one and five months after dosing (11, 12).
240 Third, while self-reported information about a previous SARS-CoV-2 infection or vaccination can impact
241 study outcome, two recent publications found a 98% consistency for vaccination type and 95% for
242 vaccination date between self-reported and administrative records or a positive predictive value of 98.2%
243 and a negative predictive value of 97.3% between a self-reported vaccination and the detection of SARS
244 CoV-2 antibodies (27, 28). Last, we only examine vaccination-induced antibody titers, omitting from our
245 study people with previous infections or boosters. While these information would be valuable, we could
246 not provide this dataset in a reasonably short time. Hence, it remains to be determined if boosters or
247 convalescence has impacts that specifically improve neutralization efficacy by defined vaccination
248 protocols.

249 Following current recommendations, a booster vaccination is generally advised after six months in many
250 countries. Although our results do not necessarily predict failure of vaccine effectiveness and omit
251 measuring cellular immunity or non-neutralizing antibody effects, it does however suggest that active
252 protection against the Omicron VoC may be reduced in many vaccinated individuals. Hence, booster
253 vaccination might be advised at earlier stages, especially for at-risk groups in the absence of a precise and
254 clinically relevant correlate of protection.

255 Overall, we provide further evidence that that amino acid mutations accumulated in the B.1.1.529 Spike
256 protein serve to escape vaccine-induced protection. In the absence of conclusive data on infectivity and
257 disease severity, development of adapted second generation vaccinations, booster doses and careful
258 monitoring of future variants of concern appears warranted.

259 **Contributors**

260 MS, HJ, LCS conceived the study. MS, GK, BL, SC, NSM, SP and LCS procured funding. GK, BL, MS,
261 MaH and DG designed the population-based cohort this study is based on. HJ, MS and LCS designed the
262 experiments. HJ, HM, MYD, UR, LA, YK and TL performed the experiments. MHa, BK, MS, JH, MYD
263 and HM performed data analysis. MS, HJ, HM, MYD generated figures and tables. MS, BK, HJ, LCS
264 verified the underlying data. MHo, SP provided reagents. AD, DJ, JH, MS, BK, PH, BL, SC, MHa, DG,
265 SG, JKH, VM, YvK were involved in sample or data collection and project administration. MS, HJ, LCS
266 wrote the manuscript. All authors critically reviewed and approved the final manuscript.

267 **Declaration of Interest**

268 NSM was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences Institute at
269 the University of Tübingen is involved in applied research projects as a fee for services with the Luminex
270 Corporation. The other authors declare no competing interest.

271 **Acknowledgments**

272 We want to thank again all parties involved in any capacity in making MuSPAD happen. Most of all the
273 study participants for their willingness and commitment to make this study possible and all colleagues at
274 the HZI, the Hannover Unified Biobank and the DRK Institute of Transfusion Medicine and
275 Immunohematology who contributed to project administration, organization and sample processing. We
276 thank Daniela Lenz, Ayse Barut, Inge Hollatz-Rangosch and Fawad Khan for excellent technical assistance
277 during this study.

278 **Data Sharing Statement**

279 Raw data is provided with the manuscript. Additional data is available upon request from the corresponding
280 authors.

281 **References**

- 282 1. WHO. WHO Coronavirus (COVID-19) Dashboard 2021 [Available from: <https://covid19.who.int/>.
- 283 2. Altmann DM, Boyton RJ, Beale R. Immunity to SARS-CoV-2 variants of concern. *Science*.
284 2021;371(6534):1103-4.
- 285 3. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of
286 Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med*. 2021;385(7):585-94.
- 287 4. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The biological and
288 clinical significance of emerging SARS-CoV-2 variants. *Nat Rev Genet*. 2021;22(12):757-73.
- 289 5. WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern 2021 [Available
290 from: [https://www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-2-](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern)
291 [variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern).
- 292 6. Zhang L, Li Q, Liang Z, Li T, Liu S, Cui Q, et al. The significant immune escape of pseudotyped
293 SARS-CoV-2 Variant Omicron. *Emerg Microbes Infect*. 2021:1-11.
- 294 7. Cele S, Jackson L, Khan K, Khoury DS, Moyo-Gwete T, Tegally H, et al. SARS-CoV-2 Omicron has
295 extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for
296 infection. *medRxiv*. 2021.
- 297 8. Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, et al. Reduced neutralisation of
298 SARS-COV-2 Omicron-B. 1.1. 529 variant by post-immunisation serum. *medRxiv*. 2021.
- 299 9. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced Neutralization of
300 SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies. *medRxiv*. 2021.
- 301 10. Schubert M, Bertoglio F, Steinke S, Heine PA, Ynga-Durand MA, Zuo F, et al. Human serum from
302 SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2
303 Omicron variant. *medRxiv*. 2021.
- 304 11. Schmidt F, Muecksch F, Weisblum Y, Silva JD, Bednarski E, Cho A, et al. Plasma neutralization
305 properties of the SARS-CoV-2 Omicron variant. *medRxiv*. 2021.
- 306 12. Rössler A, Riepler L, Bante D, Laer Dv, Kimpel J. SARS-CoV-2 B.1.1.529 variant (Omicron) evades
307 neutralization by sera from vaccinated and convalescent individuals. *medRxiv*. 2021.
- 308 13. Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, et al. The Omicron variant is
309 highly resistant against antibody-mediated neutralization – implications for control of the COVID-19
310 pandemic. *bioRxiv*. 2021.
- 311 14. Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. mRNA-
312 based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.
313 *medRxiv*. 2021.
- 314 15. Gorny D, Harries M, Glöckner S, Strengert M, Kerrinnes T, Heise J-K, et al. SARS-CoV-2
315 seroprevalence in Germany. *Deutsches Ärzteblatt international*. 2021.
- 316 16. Becker M, Strengert M, Junker D, Kaiser PD, Kerrinnes T, Traenkle B, et al. Exploring beyond
317 clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-
318 reactivity. *Nature communications*. 2021;12(1):1152.
- 319 17. Hoffmann M, Zhang L, Kruger N, Graichen L, Kleine-Weber H, Hofmann-Winkler H, et al. SARS-
320 CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. *Cell Rep*.
321 2021;35(3):109017.
- 322 18. Hoffmann M, Arora P, Gross R, Seidel A, Hornich BF, Hahn AS, et al. SARS-CoV-2 variants B.1.351
323 and P.1 escape from neutralizing antibodies. *Cell*. 2021;184(9):2384-93 e12.
- 324 19. Brinkmann C, Hoffmann M, Lubke A, Nehlmeier I, Kramer-Kuhl A, Winkler M, et al. The
325 glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive
326 cells. *PLoS One*. 2017;12(12):e0189073.

- 327 20. Kleine-Weber H, Elzayat MT, Wang L, Graham BS, Muller MA, Drosten C, et al. Mutations in the
328 Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase
329 Resistance to Antibody-Mediated Neutralization. *J Virol*. 2019;93(2).
- 330 21. Berger Rentsch M, Zimmer G. A vesicular stomatitis virus replicon-based bioassay for the rapid
331 and sensitive determination of multi-species type I interferon. *PLoS One*. 2011;6(10):e25858.
- 332 22. Aggarwal A, Stella AO, Walker G, Akerman A, Milogiannakis V, Brilot F, et al. SARS-CoV-2
333 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to
334 viral variants of concern. *medRxiv*. 2021:2021.12.14.21267772.
- 335 23. Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, et al. Dynamics of antibody
336 response to BNT162b2 vaccine after six months: a longitudinal prospective study. *The Lancet Regional
337 Health - Europe*. 2021;10:100208.
- 338 24. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 Antibody
339 Response Following Vaccination With BNT162b2 and mRNA-1273. *Jama*. 2021;326(15):1533-5.
- 340 25. Shrotri M, Fragaszy E, Geismar C, Nguyen V, Beale S, Braithwaite I, et al. Spike-antibody
341 responses to ChAdOx1 and BNT162b2 vaccines by demographic and clinical factors (Virus Watch study).
342 *medRxiv*. 2021:2021.05.12.21257102.
- 343 26. Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, Feng W, et al. Booster of mRNA-1273
344 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies. *medRxiv*.
345 2021:2021.12.15.21267805.
- 346 27. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K-D, et al. Impact of
347 vaccination on new SARS-CoV-2 infections in the United Kingdom. *Nature Medicine*. 2021;27(8):1370-8.
- 348 28. Siegler AJ, Luisi N, Hall EW, Bradley H, Sanchez T, Lopman BA, et al. Trajectory of COVID-19
349 Vaccine Hesitancy Over Time and Association of Initial Vaccine Hesitancy With Subsequent Vaccination.
350 *JAMA Network Open*. 2021;4(9):e2126882-e.

351

352

353 **Table 1. Sample characteristics** (na: not applicable)
 354

| Sample cohort (n) | ΔT (days) post-complete vaccination (mean, SD) | ΔT (days) between doses (mean, SD) | Age (years), median (IQR) | Sex (n, %) | |
|--|--|--|---------------------------|------------|-----------|
| | | | | Female | Male |
| two-dose BNT162b2 T1* (15) | 28.3 (4.8) | 21.3 (1.2) | 50 (39-56) | 12 (80.0) | 3 (20.0) |
| two-dose BNT162b2 T2* (15) | 173.6 (11.4) | | 50 (40-57) | | |
| two-dose mRNA-1273 (16) | 28.5 (4.2) | 32.0 (6.1) | 56 (54-68) | 11 (68.8) | 5 (31.2) |
| first dose AZD1222, second dose mRNA-1273 (11) | 28.2 (4.4) | 65.4 (21.6) | 68 (65-73) | 7 (63.7) | 4 (36.4) |
| first dose AZD1222, second dose BNT162b2 (15) | 26.0 (4.1) | 76.2 (7.7) | 67 (65-69) | 4 (26.7) | 11 (73.4) |
| two-dose AZD1222 (14) | 27.1 (1.2) | 77.6 (1.8) | 65 (63-69) | 7 (50.0) | 7 (50.0) |
| one-dose Ad26.CoV2.S (11) | 55.3 (5.4) | na | 61 (58-63) | 7 (63.6) | 4 (36.4) |

* Two-dose BNT162b2 T1 and two-dose BNT162b2 T2 are paired longitudinal samples.

355
356

Table 2. Geometric means of responses and fold changes in Omicron responder subsets


| Vaccination regimen | GMT (95% CI) of paired <u>responders</u> | | | |
|--|--|------------------------|-------------------------|----------------------|
| | B.1 | Beta | Delta | Omicron |
| two-dose mRNA-1273 | 526.0 (368.1-751.5) | 119.6 (70.7-202.5) | 481.5 (70.7-202.5) | 33.2 (21.2-52.2) |
| first dose AZD1222, second dose BNT162b2 | 902.8 (572.0-1425.0) | 173.9 (109.0-277.5) | 173.9 (109.0-277.5) | 61.5 (44.0-85.9) |
| first dose AZD1222, second dose mRNA-1273 | 1323.0 (740.6-2363.0) | 368.9 (156.9-867.3) | 923.8 (418.5-2039.0) | 75.6 (41.2-138.9) |
| two-dose AZD1222 | 186.4 (91.2-381.3) | 46.4 (20.8-103.5) | 95.3 (41.5-232.9) | 14.6 (7.0-30.5) |
| one-dose Ad26.CoV2.S* | na | na | na | na |
| two-dose BNT162b2 T1 ** | 393.0 (213.5-723.6) | 56.6 (14.3-223.5) | 503.5 (275.2-921.0) | 13.7 (7.8-24.1) |
| two-dose BNT162b2 T2 ** | 82.6 (60.1-113.6) | 31.3 (16.8-58.2) | 85.7 (51.4-142.7) | 10.9 (7.3-16.5) |
| Vaccination regimen | Fold change in GMT of paired <u>responders</u> | | | |
| | B.1 | Beta | Delta | Omicron |
| two-dose mRNA-1273 | - | -4.4 | -1.1 | -15.8 |
| first dose AZD1222, second dose BNT162b2 | - | -5.2 | -1.6 | -14.7 |
| first dose AZD1222, second dose mRNA-1273 | - | -3.6 | -1.4 | -17.5 |
| two-dose AZD1222 | - | -4.0 | -1.9 | -12.8 |
| one-dose Ad26.CoV2.S* | - | na | na | na |
| two-dose BNT162b2 T1 ** | - | -6.9 | -0.8 | -28.7 |
| two-dose BNT162b2 T2 ** | - | -2.6 | -1.0 | -7.5 |

* Only one subject showed detectable neutralization titers in the Omicron assay.

** Two-dose BNT162b2 T1 and two-dose BNT162b2 T2 are paired longitudinal samples.


357

358 **Figures with legends**



359
360 **Fig. 1. Impact of SARS-CoV-2 vaccination schemes on neutralization response towards Omicron (B.1.1.529)**
361 **variant.**

362 Vaccination-induced neutralization potency against Omicron (B.1.1.529), Beta (B. 1.351), Delta (B.1.617.2) or
363 Wuhan (B.1) pseudotypes was measured in individuals who received a vector-based vaccination with single dose
364 Ad26.CoV2.S (n=11, a), two doses of AZD1222 (n=14, b), two doses of mRNA vaccine BNT162b2 (n=15, c), a
365 heterologous two-dose vaccination with AZD1222-BNT162b2 (n=15, d) or AZD1222-mRNA-1273 (n=11, e), or two
366 doses of mRNA vaccine mRNA-1273 (n=16, f) 21 to 61 days after the last dose. FRNT₅₀ data is expressed for each
367 serum sample, bold horizontal lines and whiskers are geometric means with 95% CI. Interconnecting lines represent
368 sample data from the same donor. Non-neutralizing sample values were arbitrarily set to 1 for presentation purposes,
369 indicated by a dashed line. Fold change in neutralization potency between SARS-CoV-2 wild-type and VoC
370 pseudotypes is shown below p-values. Percentage (%) responder rates and FRNT₅₀ geometric mean titers (GMT)
371 per SARS-CoV-2 pseudotype are shown above the individual measurements. Fold change in neutralization potency and
372 GMTs for SARS-CoV-2 pseudotypes are only calculated for groups where all samples had a detectable neutralizing
373 activity, or else not applicable (na) is stated. Time between sampling and full vaccination in days is displayed as mean
374 and SD below the vaccination scheme. Statistical analysis was performed by paired non-parametric Friedman's test
375 followed by a Dunn's multiple comparison analysis. Statistical significance was defined by a value of * <0.05 ; **
376 <0.01 ; *** <0.001 ; **** <0.0001 .



377

378 **Fig. 2. Longitudinal BNT162b2 neutralization response towards SARS-CoV-2 VoC Omicron (B.1.1.529).**
 379 Neutralization capacity towards SARS-CoV-2 Omicron (B.1.1.529), Beta (B. 1.351), Delta (B.1.617.2) or Wuhan
 380 (B.1) pseudotypes was analyzed approximately six months after a two-dose BNT162b2 vaccination (n=15, a).
 381 Neutralization kinetic of paired longitudinal samples towards SARS-CoV-2 B.1 (b), Beta (c), Delta (d) and Omicron
 382 (e) pseudotypes is shown between T1 (n=15; mean (SD) Δ T after last dose: 28.3 (4.3)) and T2 (n=15; mean (SD) Δ T
 383 after last dose: 173.6 (11.4)). Peak neutralization responses of BNT162b2-vaccinated individuals from Figure 1c are
 384 displayed for clarity and comparison (b-e). FRNT₅₀ data is expressed for each serum sample, bold horizontal lines and
 385 whiskers are geometric means with 95% CI. Interconnecting lines represent sample data from the same donor (a-e).
 386 Non-neutralizing samples were arbitrarily set to 1 for presentation purposes, indicated by a dashed line. Fold change
 387 in neutralization potency between SARS-CoV-2 wild-type and VoC pseudotypes is shown below p-values. Percentage
 388 (%) responder rates and FRNT₅₀ geometric mean titers (GMT) per SARS-CoV-2 pseudotype are shown above the
 389 individual measurements. Fold change in neutralization potency and GMTs for SARS-CoV-2 pseudotypes are only
 390 calculated for groups where all samples had a detectable neutralizing activity, or else not applicable (na) is stated.
 391 Statistical analysis was performed by paired non-parametric Friedman's test followed by a Dunn's multiple comparison
 392 analysis (a) or a by two-tailed Wilcoxon matched-pairs signed rank test (b-e). Statistical significance was defined by
 393 a value of *<0.05; ** <0.01; ***<0.001; ****<0.0001.